2021 Q4 Form 10-Q Financial Statement

#000155837021015506 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.782M $5.239M $4.612M
YoY Change 50.57% 31.57% 755.66%
% of Gross Profit
Research & Development $15.98M $12.52M $11.91M
YoY Change 153.97% 167.99% 511.71%
% of Gross Profit
Depreciation & Amortization $73.00K $50.00K $30.00K
YoY Change 900.0% 1400.0%
% of Gross Profit
Operating Expenses $21.76M $17.76M $16.52M
YoY Change 114.78% 125.75% 564.6%
Operating Profit -$17.76M -$16.52M
YoY Change 125.75% 564.6%
Interest Expense $109.0K $105.0K $117.0K
YoY Change -117.68% 254.55%
% of Operating Profit
Other Income/Expense, Net $10.00K $49.00K $116.0K
YoY Change 104.17% 251.52%
Pretax Income -$21.64M -$17.71M -$16.41M
YoY Change 113.6% 47.73% 568.81%
Income Tax
% Of Pretax Income
Net Earnings -$21.64M -$17.71M -$16.41M
YoY Change 113.6% 125.82% 568.81%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$0.42
Diluted Earnings Per Share -$544.4K -$0.45 -$0.42
COMMON SHARES
Basic Shares Outstanding 40.29M 39.61M 39.42M
Diluted Shares Outstanding 39.61M 39.42M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $287.3M $306.0M $318.1M
YoY Change -15.14% 139.4%
Cash & Equivalents $13.81M $25.60M $50.42M
Short-Term Investments $273.4M $280.4M $267.7M
Other Short-Term Assets $3.435M $2.326M $2.710M
YoY Change -1.86% 93.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $290.7M $308.3M $320.9M
YoY Change -15.04% 138.79%
LONG-TERM ASSETS
Property, Plant & Equipment $1.474M $975.0K $866.0K
YoY Change 1865.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $540.0K $540.0K $510.0K
YoY Change 5.88% -66.25%
Total Long-Term Assets $5.260M $1.515M $1.376M
YoY Change 799.15% -5.31%
TOTAL ASSETS
Total Short-Term Assets $290.7M $308.3M $320.9M
Total Long-Term Assets $5.260M $1.515M $1.376M
Total Assets $295.9M $309.8M $322.2M
YoY Change -13.65% 137.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $23.00K $306.0K $385.0K
YoY Change -96.8% 206.0%
Accrued Expenses $8.530M $8.035M $6.971M
YoY Change 175.16% 86.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.019M $8.901M $8.146M
YoY Change 96.71% 67.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.358M
YoY Change
Total Long-Term Liabilities $2.358M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $9.019M $8.901M $8.146M
Total Long-Term Liabilities $2.358M $0.00 $0.00
Total Liabilities $11.38M $8.901M $8.146M
YoY Change 148.14% 67.94%
SHAREHOLDERS EQUITY
Retained Earnings -$104.2M -$82.55M -$64.84M
YoY Change 214.83%
Common Stock $3.000K $3.000K $3.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $284.6M $300.9M $314.1M
YoY Change
Total Liabilities & Shareholders Equity $295.9M $309.8M $322.2M
YoY Change -13.65% 137.03%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$21.64M -$17.71M -$16.41M
YoY Change 113.6% 125.82% 568.81%
Depreciation, Depletion And Amortization $73.00K $50.00K $30.00K
YoY Change 900.0% 1400.0%
Cash From Operating Activities -$18.60M -$12.10M -$8.909M
YoY Change 106.24% 60.6% 654.36%
INVESTING ACTIVITIES
Capital Expenditures -$699.0K -$96.00K -$360.0K
YoY Change 1298.0% -2020.0% 5900.0%
Acquisitions
YoY Change
Other Investing Activities $6.699M -$12.69M $11.29M
YoY Change
Cash From Investing Activities $6.000M -$12.78M $10.93M
YoY Change -12100.0% -255780.0% -182200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 818.0K 57.00K 516.0K
YoY Change -99.63% -99.93% -97.83%
NET CHANGE
Cash From Operating Activities -18.60M -12.10M -8.909M
Cash From Investing Activities 6.000M -12.78M 10.93M
Cash From Financing Activities 818.0K 57.00K 516.0K
Net Change In Cash -11.78M -24.82M 2.533M
YoY Change -105.59% -132.1% -88.78%
FREE CASH FLOW
Cash From Operating Activities -$18.60M -$12.10M -$8.909M
Capital Expenditures -$699.0K -$96.00K -$360.0K
Free Cash Flow -$17.90M -$12.00M -$8.549M
YoY Change 99.6% 59.22% 627.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.29
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39607745
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2617543
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39450655
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2617543
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39607745
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2617543
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39450655
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2617543
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2020Q4 us-gaap Assets Current
AssetsCurrent
342137000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
975000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
540000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.29
dei Entity Central Index Key
EntityCentralIndexKey
0001750284
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39712
dei Entity Registrant Name
EntityRegistrantName
OLEMA PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0409740
dei Entity Address Address Line1
EntityAddressAddressLine1
512 2nd Street, 4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address Country
EntityAddressCountry
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94107
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
243-5555
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
OLMA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40287641
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25597000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
338549000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
280357000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3588000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
308280000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
510000
CY2021Q3 us-gaap Assets
Assets
309795000
CY2020Q4 us-gaap Assets
Assets
342722000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
306000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
719000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8595000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3866000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8901000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4585000
CY2021Q3 us-gaap Liabilities
Liabilities
8901000
CY2020Q4 us-gaap Liabilities
Liabilities
4585000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40277390
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40169738
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39681298
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39308238
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
383428000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
371228000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82552000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33094000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
300894000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
338137000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
309795000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
342722000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12523000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4673000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35125000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7415000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5239000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3195000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14609000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3982000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
17762000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
7868000
us-gaap Operating Expenses
OperatingExpenses
49734000
us-gaap Operating Expenses
OperatingExpenses
11397000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17762000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7868000
us-gaap Operating Income Loss
OperatingIncomeLoss
-49734000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11397000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
105000
CY2020Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
23000
us-gaap Investment Income Interest
InvestmentIncomeInterest
333000
us-gaap Investment Income Interest
InvestmentIncomeInterest
59000
us-gaap Interest Expense
InterestExpense
653000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-57000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
49000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
24000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
276000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-593000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17713000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7844000
us-gaap Net Income Loss
NetIncomeLoss
-49458000
us-gaap Net Income Loss
NetIncomeLoss
-11990000
CY2020Q3 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
1869000
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
1869000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17713000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9713000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49458000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13859000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.29
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39607745
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2617543
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39450655
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2617543
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17713000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7844000
us-gaap Net Income Loss
NetIncomeLoss
-49458000
us-gaap Net Income Loss
NetIncomeLoss
-11990000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
29000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
15000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17684000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7844000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49443000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11990000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
314084000
CY2021Q3 olma Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodValue
280000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4125000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
32000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
29000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17713000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
300894000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
338137000
olma Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodValue
341000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
187000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
386000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11140000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
146000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
15000
us-gaap Net Income Loss
NetIncomeLoss
-49458000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
300894000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-13952000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
582000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7844000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-22963000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-10594000
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1054000
olma Adjustments To Additional Paid In Capital Repurchase Of Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalRepurchaseOfConvertibleDebtWithConversionFeature
2568000
olma Adjustments To Additional Paid In Capital Extinguishment Of Convertible Notes
AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfConvertibleNotes
2148000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
120000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
736000
us-gaap Net Income Loss
NetIncomeLoss
-11990000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-22963000
us-gaap Net Income Loss
NetIncomeLoss
-49458000
us-gaap Net Income Loss
NetIncomeLoss
-11990000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
90000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
7000
us-gaap Paid In Kind Interest
PaidInKindInterest
641000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-220000
us-gaap Share Based Compensation
ShareBasedCompensation
11286000
us-gaap Share Based Compensation
ShareBasedCompensation
736000
olma Prepaid Expenses And Other Current Assets And Other Assets
PrepaidExpensesAndOtherCurrentAssetsAndOtherAssets
-1232000
olma Prepaid Expenses And Other Current Assets And Other Assets
PrepaidExpensesAndOtherCurrentAssetsAndOtherAssets
1321000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-527000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-839000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
5070000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1913000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-32087000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10853000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
876000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
186449000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
467011000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-281438000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
187000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
640000
olma Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
386000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3000000
olma Proceeds From Non Recourse Notes
ProceedsFromNonRecourseNotes
88000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
889000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
573000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
138614000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-312952000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
127756000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
338549000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25597000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127824000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
114000
olma Non Cash Deferred Offering Costs Included In Other Current Liabilities
NonCashDeferredOfferingCostsIncludedInOtherCurrentLiabilities
587000
olma Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
341000
olma Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
10000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020Q4 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
23765075
CY2020Q4 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
23765075
CY2020Q4 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
148300000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
306000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Use of Estimates</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of expenses during the reporting period. Significant areas that require management’s estimates include accruals of research and development expenses, including accrual of research contract costs, share-based compensation assumptions, and fair value of common stock and convertible preferred stock prior to the IPO. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Other Risks and Uncertainties</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents, and marketable securities. The Company invests in a variety of financial instruments and, by its policy, limits these financial instruments to high credit quality securities issued by the U.S. government, U.S. government-sponsored agencies and highly rated banks and corporations, subject to certain concentration limits. The Company’s cash, cash equivalents, and marketable securities are held by financial institutions in the United States that management believes are of high credit quality. Amounts on deposit with individual banking institutions may at times exceed the limits insured by the Federal Deposit Insurance Corporation (“FDIC”); however, the Company has not experienced any losses on such deposits.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s current and potential future product candidates, uncertainty of market acceptance of the Company’s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers.</p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s product candidates require approvals from the U.S. Food and Drug Administration (“FDA”) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company were denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</p>
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
305939000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
24000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
305954000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1126000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
137000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
151000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
62000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
975000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75000
CY2021Q3 olma Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
1167000
CY2020Q4 olma Prepaid Clinical Trial Costs
PrepaidClinicalTrialCosts
1148000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
318000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1663000
CY2021Q3 olma Prepaid Subscriptions And Licenses
PrepaidSubscriptionsAndLicenses
318000
CY2021Q3 olma Prepaid Research Contracts
PrepaidResearchContracts
199000
CY2020Q4 olma Prepaid Research Contracts
PrepaidResearchContracts
432000
CY2021Q3 us-gaap Prepaid Rent
PrepaidRent
91000
CY2020Q4 us-gaap Prepaid Rent
PrepaidRent
196000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
233000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
149000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2326000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3588000
CY2021Q3 olma Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4310000
CY2020Q4 olma Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
609000
CY2021Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2111000
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1222000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
960000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
577000
CY2021Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
654000
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
444000
CY2021Q3 olma Early Exercise Of Unvested Options
EarlyExerciseOfUnvestedOptions
237000
CY2020Q4 olma Early Exercise Of Unvested Options
EarlyExerciseOfUnvestedOptions
578000
CY2021Q3 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
67000
CY2020Q4 us-gaap Accrual For Taxes Other Than Income Taxes Current
AccrualForTaxesOtherThanIncomeTaxesCurrent
198000
CY2021Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
256000
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
238000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8595000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3866000
us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
1869000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0063
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y11M23D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7707
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4776908
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.83
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M1D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
177962000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1031733
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
35.88
olma Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y3M21D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
156385
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
87668
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
22.39
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5564588
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.50
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17713000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9713000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-49458000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y10D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
71759000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1053721
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y6M25D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
21315000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4510867
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M20D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
54999000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
53588
CY2020Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
600000
CY2020Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
135525
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
4.406
CY2020Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
4.824
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
81937
CY2021Q3 us-gaap Deferred Compensation Share Based Arrangements Liability Current
DeferredCompensationShareBasedArrangementsLiabilityCurrent
200000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
735294
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.40
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
192790
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
2.40
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
542504
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
2.40
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4157000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
582000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11286000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
736000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-17713000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-7844000
us-gaap Net Income Loss
NetIncomeLoss
-49458000
us-gaap Net Income Loss
NetIncomeLoss
-11990000
CY2020Q3 us-gaap Preferred Stock Conversions Inducements
PreferredStockConversionsInducements
1869000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13859000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39607745
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2617543
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39450655
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2617543
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.29
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6124071
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28341301
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
53588
CY2021Q3 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
259000
CY2021Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
1161000
CY2021Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
973000
CY2021Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
799000
CY2021Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
822000
CY2021Q3 olma Contractual Obligation To Be Paid After Year Four
ContractualObligationToBePaidAfterYearFour
69000
CY2021Q3 us-gaap Contractual Obligation
ContractualObligation
4083000

Files In Submission

Name View Source Status
0001558370-21-015506-index-headers.html Edgar Link pending
0001558370-21-015506-index.html Edgar Link pending
0001558370-21-015506.txt Edgar Link pending
0001558370-21-015506-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
olma-20210930.xsd Edgar Link pending
olma-20210930x10q.htm Edgar Link pending
olma-20210930x10q_htm.xml Edgar Link completed
olma-20210930xex31d1.htm Edgar Link pending
olma-20210930xex31d2.htm Edgar Link pending
olma-20210930xex32.htm Edgar Link pending
olma-20210930_cal.xml Edgar Link unprocessable
olma-20210930_def.xml Edgar Link unprocessable
olma-20210930_lab.xml Edgar Link unprocessable
olma-20210930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending